Tag Archives: R&D

Scottish Life Science Sector’s Referendum Concerns

As the ‘Yes-to-Scottish-independence’ vote gathers strength in the run-up to this week’s historic referendum, some the UK’s big business players last week warned of adverse consequences if Scotland breaks away from the United Kingdom. Most controversially, the Royal Bank of Scotland (RBS) declared that a vote for independence would see it forced to relocate its […]
Posted in Biotech, Europe, Global, R&D | Also tagged , , , | Leave a comment

The Future of Oncology is Now

Applied Clinical Trials’ Lisa Henderson speaks to Novella Clinical CEO Richard Staub. Last August, Quintiles announced its intention to purchase Novella Clinical, specifically for its focus on small and mid-sized oncology biopharma clients, as well as medical device and diagnostics companies. We checked in with Novella President Richard Staub to discuss post-acquisition life, outsourcing, and […]
Posted in R&D | Also tagged , , | Leave a comment

Big Data in the Pharma R&D Landscape

Big Data and the mindset that comes with it will have a fundamental impact on how pharmaceutical research will be conducted in the future, writes Peter Tormay. Innovation is the corner stone of the pharmaceutical industry. Unfortunately, the industry as a whole is not very good at it. For the last two decades the approval […]
Posted in Guest Blog, R&D, Strategy, Technology | Also tagged , | Leave a comment

Rebranding Risk-Based Monitoring in Clinical R&D

With all of the buzz and excitement around risk-based monitoring (RBM), one might expect that the broad adoption of this emerging clinical research paradigm is well underway. Those familiar with the often painfully slow pace of innovation in the area of clinical R&D, however, will not be surprised by the more sobering reality that only […]
Posted in R&D | Also tagged , | Leave a comment

Pushing the Boundaries of MS Research: The Myelin Repair Foundation

R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
Posted in People, Strategy | Also tagged , , | 2 Comments
  • Categories

  • Meta